BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Research Pipeline
CJC-1295 and Ipamorelin: The GH Secretagogue Stack at the Centre of the 2026 Compounding Review
CJC-1295 and Ipamorelin are the most widely referenced growth hormone secretagogue combination in peptide research, but their regulatory status has been in flux for nearly three years. With their Category 2 nominations withdrawn as of April 2026 and the PCAC review scheduled for July 23–24, procurement teams need a clear picture of the pharmacology, the evidence landscape, and what the regulatory calendar means in practice.
08 Jun 2026
Research Pipeline
Thymosin Alpha-1: The Most Clinically Validated Research Peptide in the July 2026 PCAC Review
Thymosin alpha-1 (Tα1) holds a distinction no other research peptide can claim: it is approved as a prescription medicine in over 35 countries and has been evaluated in more than 11,000 human subjects across clinical trials. Yet it remains unapproved in the US and UK. With the FDA's Pharmacy Compounding Advisory Committee due to formally review the compound in July 2026, procurement teams need to understand what the evidence base actually shows — and what the regulatory inflection point means…
07 Jun 2026
Research Pipeline
GLP-1 Peptides and the Nervous System: What the 2026 Evidence Landscape Means for Research Priorities
A comprehensive review published this week confirms that GLP-1 receptor agonists present a sharply divided neurological picture: semaglutide failed to slow Alzheimer's disease progression in the Phase 3 EVOKE trials, yet evidence in Parkinson's disease and stroke prevention remains meaningfully positive. For research labs procuring GLP-1 peptides, the distinction matters.
04 Jun 2026
Research Pipeline
BPC-157's Evidence Problem: What the New Investigation Means for Labs Ahead of the July PCAC Hearing
A joint Undark/STAT News investigation published this week laid out the thin and largely single-source evidentiary base behind BPC-157 — the peptide at the centre of the FDA's July 2026 compounding review. With the public comment window closing 9 July, research procurement teams need to understand what the science does and does not yet support.
03 Jun 2026
Research Pipeline
Semax: The Russian-Approved Neuropeptide Now at the Centre of the FDA's July 2026 Compounding Review
Semax, a synthetic ACTH-derived heptapeptide approved in Russia for stroke recovery and cognitive impairment, was removed from the FDA's Category 2 restricted compounding list in April 2026 and is now scheduled for formal PCAC review on 24 July 2026. For UK research-procurement teams, its regulatory trajectory — and the evidentiary questions the advisory panel must resolve — make it one of the more consequential peptides to monitor this summer.
01 Jun 2026
Research Pipeline
Oral Peptide Therapeutics Reach an Inflection Point: ICOTYDE's Approval, Pinnacle's $89M Raise, and What the Delivery Revolution Means for Research Labs
The FDA approval of icotrokinra (ICOTYDE) as the first targeted oral peptide to block the IL-23 receptor marks a structural shift in peptide drug delivery. Combined with a wave of investment in oral-peptide platforms and an upcoming PCAC advisory meeting, the field is entering a period of rapid technical and regulatory change that procurement teams need to understand.
29 May 2026
Research Pipeline
What the 2026 Orthopaedic Literature Says About Research Peptides — and Why It Matters for Procurement
A peer-reviewed review in JAAOS: Global Research & Reviews has systematically mapped the mechanism and evidence base for BPC-157, TB-500, GHK-Cu, Ipamorelin, CJC-1295 and related compounds in musculoskeletal medicine. The findings underscore a persistent gap between preclinical promise and human trial data — a distinction that carries direct implications for research-procurement professionals sourcing these compounds and for how suppliers should frame their documentation.
28 May 2026
Research Pipeline
Thymosin Alpha-1: The Peptide With the Strongest Clinical Evidence Base — and a Complicated Regulatory Story
Thymosin alpha-1 (Tα1) is approved as a prescription drug in more than 35 countries and has been evaluated in over 80 clinical trials. Yet its US compounding status remains unsettled, and a large 2025 phase 3 trial returned a negative primary endpoint in sepsis. For UK research-procurement professionals, it is arguably the most evidence-rich peptide on the market — and among the most instructive in understanding how clinical nuance shapes regulatory outcome.
24 May 2026
Research Pipeline
GHK-Cu: The Copper Tripeptide Facing Its Second Regulatory Wave — What Research Labs Need to Know
GHK-Cu (copper tripeptide-1) has one of the stronger mechanistic evidence bases among research peptides, spanning wound healing, collagen remodelling, and genomic modulation of over a thousand genes. Following the FDA's April 2026 Federal Register notice, it now sits in the second wave of PCAC review, scheduled before February 2027. This briefing covers its biochemistry, the state of the clinical evidence, and what the split regulatory picture means for UK procurement teams.
24 May 2026
Research Pipeline
TRIUMPH-4 read-out: retatrutide hits 28.7% weight loss but a new dysesthesia signal complicates the path to filing
Eli Lilly's triple-agonist retatrutide produced the highest weight-loss percentage ever recorded in a Phase 3 obesity trial in TRIUMPH-4, but a new dysesthesia signal — not seen in Phase 2 — affected one in five patients on the top dose. With seven further Phase 3 read-outs scheduled across 2026, the next nine months will determine whether retatrutide rewrites the GLP-1 competitive map or carries a safety footnote into the label.
18 May 2026
Research Pipeline
Foundayo (Orforglipron) Sustains Most Injectable GLP-1 Weight Loss in Phase 3b Switch Trial, New Data Show
A Phase 3b trial published in Nature Medicine on 12 May 2026 shows that patients who switched from injectable tirzepatide or semaglutide to once-daily oral orforglipron (Foundayo) retained 75–79% of their prior weight loss over 52 weeks. The data, presented simultaneously at the European Congress on Obesity, add clinical depth to an already-approved drug and sharpen the debate over whether oral small-molecule GLP-1 agonists can serve as maintenance therapy after injectable induction.
15 May 2026
Research Pipeline
Oral Small-Molecule GLP-1 Drugs Reach Deep Brain Reward Circuits, Pointing Towards Addiction Research Applications
A Nature study published 6 May 2026 found that oral small-molecule GLP-1 receptor agonists, including orforglipron and danuglipron, suppress hedonic feeding in mice by modulating a reward circuit in the central amygdala — a mechanism distinct from the hypothalamic appetite pathways activated by peptide-based GLP-1 drugs. The findings add mechanistic weight to a growing body of evidence linking GLP-1 pharmacology to reduced substance use disorder risk.
08 May 2026